A Phase II Trial of Chemotherapy-Free Neoadjuvant Camrelizumab plus Apatinib for Resectable HNSCC: Pathologic Response and Vascular–Immune Cross-talk
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1158/1078-0432.ccr-26-0466
其他信息:
出版社: American Association for Cancer Research (AACR)
作者: Yaqiong Jie; Zhuo Chen; Lihuang Chen; Yushuo Zhang; Min Li; Li Zhang; Alfred King-Yin Lam; Jie Qiao; Yi Liu; Xinguang Han; Bin Qiao
全文下载地址: https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-26-0466/3828505/ccr-26-0466.pdf

